Home › Neuroendocrine Tumors › California › Mountain View
Neuroendocrine Tumors clinical trials in Mountain View, CA
5 studies for Neuroendocrine Tumors are looking for participants at sites in and around Mountain View (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- Stanford Cancer Center, Palo Alto · 5 mi away
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi away
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
RecruitingPhase 1/2
- Stanford University, Palo Alto · 5 mi away
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
- Stanford Cancer Institute, Stanford · 5 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Stanford · 5 mi away
Neuroendocrine Tumors trials in other cities
- Washington, DC11 studies
- Philadelphia, PA11 studies
- Rochester, MN9 studies
- Columbus, OH8 studies
- St. Louis, MO8 studies
- Houston, TX8 studies
- Salt Lake City, UT8 studies
- Chicago, IL7 studies
- New York City, NY7 studies
- Cleveland, OH7 studies
- Cedar Rapids, IA7 studies
- Miami, FL7 studies
Other studies in Mountain View
- Cancer (all types)40 studies
- Breast Cancer25 studies
- Metastatic Cancer25 studies
- Non-Small Cell Lung Cancer21 studies
- Acute Myeloid Leukemia19 studies
- Ovarian Cancer19 studies
- Autism Spectrum Disorder17 studies
- Lung Cancer17 studies
- Heart Failure15 studies
- Prostate Cancer15 studies
- Autism13 studies
- Acute Lymphoblastic Leukemia13 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.